MARKET

VRCA

VRCA

Verrica Pharmaceuticals
NASDAQ

Real-time Quotes | Nasdaq Last Sale

13.71
-0.49
-3.45%
Closed 16:00 02/26 EST
OPEN
14.21
PREV CLOSE
14.20
HIGH
14.74
LOW
13.50
VOLUME
43.24K
TURNOVER
--
52 WEEK HIGH
16.91
52 WEEK LOW
6.02
MARKET CAP
354.62M
P/E (TTM)
-9.1651
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Verrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference
WEST CHESTER, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verri...
GlobeNewswire · 6d ago
H.C. Wainwright Keeps a Buy Rating on Verrica Pharmaceuticals (VRCA)
In a report released today, Oren Livnat from H.C. Wainwright reiterated a Buy rating on Verrica Pharmaceuticals (VRCA), with a price target of $21.00. The
SmarterAnalyst · 02/17 17:35
DJ Verrica Pharmaceuticals Is Maintained at Buy by Needham
Dow Jones · 02/17 16:48
DJ Verrica Pharmaceuticals Price Target Raised to $22.00/Share From $17.00 by Needham
Dow Jones · 02/17 16:48
DJ Verrica Pharmaceuticals Resubmitted NDA Gets FDA Acceptance for Filing
Dow Jones · 02/17 12:54
FDA accepts Verrica's VP-102 NDA resubmission for review
Verrica Pharmaceuticals (VRCA) announces that its resubmitted New Drug Application for VP-102 (cantharidin 0.7% Topical Solution), a proprietary topical therapy for the treatment of molluscum contagiosum (molluscum), has been accepted by
Seekingalpha · 02/17 12:53
Verrica Pharmaceuticals Announces FDA Filing Acceptance Of Resubmitted New Drug Application For VP-102 For The Treatment Of Molluscum Contagiosum
- PDUFA goal date assigned is June 23, 2021 - - VP-102 (cantharidin 0.7% Topical Solution) could potentially be the first FDA-approved treatment for molluscum contagiosum, a highly contagious viral skin
PDUFA goal date assigned is June 23, 2021 - - VP-102 (cantharidin 0.7% Topical Solution) could potentially be the first FDA-approved treatment for molluscum contagiosum, a highly contagious viral skin · 02/17 12:32
Verrica Pharmaceuticals' New-Drug Application for VP-102 Accepted by FDA
MT Newswires · 02/17 09:53
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of VRCA. Analyze the recent business situations of Verrica Pharmaceuticals through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 5 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average VRCA stock price target is 20.00 with a high estimate of 25.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 69
Institutional Holdings: 9.52M
% Owned: 36.80%
Shares Outstanding: 25.87M
TypeInstitutionsShares
Increased
16
129.78K
New
9
79.19K
Decreased
12
180.73K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.05%
Pharmaceuticals & Medical Research
-0.68%
Key Executives
Chairman/Director
Paul Manning
President/Chief Executive Officer/Director
Ted White
Chief Financial Officer
Brian Davis
General Counsel/Secretary
Christopher Hayes
Other
Joe Bonaccorso
Other
Patrick Burnett
Other
Bradley Catalone
Other
Gary Goldenberg
Director
Lawrence Eichenfield
Director
Diem Nguyen
Director
Sean Stalfort
Independent Director
Craig Ballaron
Independent Director
Mark Prygocki
  • Dividends
  • Splits
  • Insider Activity
No Data
About VRCA
Verrica Pharmaceuticals Inc. is a United States-based clinical-stage medical dermatology company. The Company is focused on identifying, developing and commercializing pharmaceutical products for the treatment of skin diseases with unmet needs. Its lead product candidate, VP-102, is a drug-device combination of topical solution of cantharidin. The Company also intends to develop second cantharidin-based product candidate, VP-103, for the treatment of plantar warts. The Company has completed one Phase II clinical trial of topical solution of cantharidin administered with the wooden stick part of a cotton-tipped swab. It also conducting another Phase II clinical trial of topical solution of cantharidin administered through applicator, which collectively refer to as VP-102, for the treatment of molluscum.

Webull offers kinds of Verrica Pharmaceuticals Inc stock information, including NASDAQ:VRCA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VRCA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading VRCA stock methods without spending real money on the virtual paper trading platform.